However, because roughly one third of MCL patients fail to respond to BTK inhibition upfront and essentially all responders eventually develop resistance to the drug, the methods to evaluate and monitor its effect on lymphoma cells are critical for optimizing personalized patient management [9–11,17]. The gene discussed is BTK; the disease is lymphoma.